Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

Diabetes Metab Syndr. 2020 Jul-Aug;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004. Epub 2020 Apr 9.

Abstract

Background and aims: High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes who develop COVID-19 infection.

Methods: PubMed database and Google Scholar were searched using the key terms 'COVID-19', 'SARS-CoV-2', 'diabetes', 'antidiabetic therapy' up to April 2, 2020. Full texts of the retrieved articles were accessed.

Results: There is evidence of increased incidence and severity of COVID-19 in patients with diabetes. COVID-19 could have effect on the pathophysiology of diabetes. Blood glucose control is important not only for patients who are infected with COVID-19, but also for those without the disease. Innovations like telemedicine are useful to treat patients with diabetes in today's times.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme 2
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Betacoronavirus*
  • Blood Glucose / analysis
  • Blood Glucose / metabolism
  • COVID-19
  • Comorbidity*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / mortality
  • Diabetes Mellitus / epidemiology*
  • Diabetes Mellitus / physiopathology
  • Diabetes Mellitus / therapy
  • Dipeptidyl Peptidase 4
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Interleukin-6
  • Mice
  • Pandemics
  • Peptidyl-Dipeptidase A
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / mortality
  • Prognosis
  • PubMed
  • Risk Factors
  • SARS-CoV-2
  • Telemedicine

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Blood Glucose
  • Hypoglycemic Agents
  • Interleukin-6
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2